Faster cancer diagnosis by suspected cancer type

The share diagnosed or having cancer ruled out within 28 days, from breast and lung pathways to non-specific symptoms.

Embed this viewUpdated 16 Aug

Data access

Use the machine-readable JSON record or the flattened CSV download or the compact Markdown version.

Preview the latest 18 observations
SeriesPeriod or categoryValueUnit
ValueMissing or Invalid58.8235% diagnosed or ruled out within 28 days · 2026-06
Valuecancer - non-specific symptoms68.5096% diagnosed or ruled out within 28 days · 2026-06
Valuelower gastrointestinal cancer69.3741% diagnosed or ruled out within 28 days · 2026-06
Valueurological malignancies (excluding testicular)72.4181% diagnosed or ruled out within 28 days · 2026-06
Valuehaematological malignancies (excluding acute leukaemia)73.5562% diagnosed or ruled out within 28 days · 2026-06
Valuegynaecological cancer73.5736% diagnosed or ruled out within 28 days · 2026-06
Valueupper gastrointestinal cancer76.7442% diagnosed or ruled out within 28 days · 2026-06
Valuehead & neck cancer79.1057% diagnosed or ruled out within 28 days · 2026-06
Valuesarcoma84.8214% diagnosed or ruled out within 28 days · 2026-06
Valuelung cancer84.9509% diagnosed or ruled out within 28 days · 2026-06
Valuetesticular cancer87.1795% diagnosed or ruled out within 28 days · 2026-06
Valuechildren's cancer87.7095% diagnosed or ruled out within 28 days · 2026-06
Valueother cancer88.5714% diagnosed or ruled out within 28 days · 2026-06
Valuebreast cancer90.7324% diagnosed or ruled out within 28 days · 2026-06
Valueskin cancer90.9807% diagnosed or ruled out within 28 days · 2026-06
Valuebrain/central nervous system tumours91.25% diagnosed or ruled out within 28 days · 2026-06
ValueExhibited (non-cancer) breast symptoms - cancer not initially suspected93.029% diagnosed or ruled out within 28 days · 2026-06
Valueacute leukaemia100% diagnosed or ruled out within 28 days · 2026-06

Methodology

Latest provider-level Faster Diagnosis Standard activity, aggregated across NHS London-region providers by suspected cancer type. Rates use within-standard activity divided by total eligible activity. The lowest-performing pathway is ranked first; small pathways can move sharply month to month and the latest data are provisional.

Provenance

Cadence
monthly
Engine
comparison

Keep going